Hollencrest Capital Management’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Hollencrest Capital Management’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$46.3K	Hold	516	–	–	﹤0.01%	584
2026 Q1	$40.9K	Hold	516	–	–	﹤0.01%	595
2025 Q4	$42.4K	Hold	516	–	–	﹤0.01%	595
2025 Q3	$36.1K	Hold	516	–	–	﹤0.01%	606
2025 Q2	$33.1K	Hold	516	–	–	﹤0.01%	581
2025 Q1	$32.8K	Hold	516	–	–	﹤0.01%	579
2024 Q4	$34.4K	Hold	516	–	–	﹤0.01%	600
2024 Q3	$36.1K	Hold	516	–	–	﹤0.01%	564
2024 Q2	$33.5K	Hold	516	–	–	﹤0.01%	581
2024 Q1	$33.4K	Hold	516	–	–	﹤0.01%	548
2023 Q4	$34K	Hold	516	–	–	﹤0.01%	542
2023 Q3	$29.5K	Hold	516	–	–	﹤0.01%	556
2023 Q2	$31.6K	Hold	516	–	–	﹤0.01%	560
2023 Q1	$32.4K	Hold	516	–	–	﹤0.01%	551
2022 Q4	$32.8K	Buy	+516	New	+$32.7K	﹤0.01%	529

Other funds holding PBE

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $18.2B AUM 22.02% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

GKWIM

Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.75B AUM 28.61% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $110B AUM 26.29% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

Hollencrest Capital Management's PBE Position: Q2 2026 in Review

Hollencrest Capital Management held its Invesco Biotechnology & Genome ETF (PBE) position steady in Q2 2026 at 516 shares worth $46.3K. The position accounts for ﹤0.01% of the portfolio, ranked #584.

Hollencrest Capital Management first reported a position in PBE in Q4 2022 and has held it in 15 quarters since. 105 funds tracked by Wall St. Rank hold PBE as of Q2 2026.

Hollencrest Capital Management held 516 shares of Invesco Biotechnology & Genome ETF worth $46.3K as of Q2 2026.
Hollencrest Capital Management left its Invesco Biotechnology & Genome ETF share count unchanged in Q2 2026.
Invesco Biotechnology & Genome ETF made up ﹤0.01% of Hollencrest Capital Management's portfolio in Q2 2026, its #584 holding.
Hollencrest Capital Management first reported a position in Invesco Biotechnology & Genome ETF in Q4 2022 and has held it in 15 quarters since.
105 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2026.

Based on Hollencrest Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.